00-BMT-126: A Phase III Clinical Trial of Immunotherapy with Humanized LL2 IgG (Epratuzumab) in Patients with Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) (IM-T-hLL2-07)